MA47576A - Composés inhibiteurs d'oga bicyclique - Google Patents
Composés inhibiteurs d'oga bicycliqueInfo
- Publication number
- MA47576A MA47576A MA047576A MA47576A MA47576A MA 47576 A MA47576 A MA 47576A MA 047576 A MA047576 A MA 047576A MA 47576 A MA47576 A MA 47576A MA 47576 A MA47576 A MA 47576A
- Authority
- MA
- Morocco
- Prior art keywords
- bicyclic
- inhibitor compounds
- oga inhibitor
- oga
- compounds
- Prior art date
Links
- 229940126137 O-GlcNAcase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16204834 | 2016-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47576A true MA47576A (fr) | 2020-01-01 |
Family
ID=57570521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047576A MA47576A (fr) | 2016-12-16 | 2017-12-15 | Composés inhibiteurs d'oga bicyclique |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190359609A1 (fr) |
| EP (1) | EP3555094A1 (fr) |
| JP (1) | JP2020503300A (fr) |
| CN (1) | CN110312716A (fr) |
| AU (1) | AU2017378182A1 (fr) |
| CA (1) | CA3044762A1 (fr) |
| MA (1) | MA47576A (fr) |
| WO (1) | WO2018109198A1 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108601B (zh) | 2014-08-28 | 2021-08-20 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| ES2765738T3 (es) | 2015-11-02 | 2020-06-10 | Janssen Pharmaceutica Nv | Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| SG11201807012QA (en) | 2016-02-25 | 2018-09-27 | Asceneuron S A | Acid addition salts of piperazine derivatives |
| AU2017222964B2 (en) | 2016-02-25 | 2020-01-02 | Asceneuron S. A. | Glycosidase inhibitors |
| WO2017144633A1 (fr) | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Inhibiteurs de glycosidases |
| EP3535269B1 (fr) | 2016-11-02 | 2020-12-09 | Janssen Pharmaceutica NV | Composés de [1,2,4]triazolo[1,5-a]pyrimidine comme inhibiteurs de pde2 |
| UA125302C2 (uk) | 2016-11-02 | 2022-02-16 | Янссен Фармацевтика Нв | Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2 |
| KR20190067788A (ko) | 2016-11-02 | 2019-06-17 | 얀센 파마슈티카 엔.브이. | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물 |
| CA3045745A1 (fr) * | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Derives de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitues par de la piperidine, de la morpholine ou de la piperazine utilises en tant qu'inhibiteurs d'oga |
| WO2019037860A1 (fr) | 2017-08-24 | 2019-02-28 | Asceneuron S.A. | Inhibiteurs linéaires de la glycosidase |
| CN118955490A (zh) * | 2018-03-14 | 2024-11-15 | 渤健马萨诸塞州股份有限公司 | O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂 |
| US11459324B2 (en) | 2018-03-14 | 2022-10-04 | Biogen Ma Inc. | O-glycoprotein-2-acetamido-2-deoxy-3-D-glycopyranosidase inhibitors |
| EP3829716B1 (fr) | 2018-07-31 | 2023-02-01 | Eli Lilly and Company | Composés 5-méthyl-4-fluoro-thiazol-2-yl |
| MA53429A (fr) | 2018-08-22 | 2022-03-30 | Asceneuron Sa | Sels d'addition d'acide succinate et fumarate de dérivés de pipérazine utiles en tant qu'inhibiteurs de glycosidase |
| WO2020039029A1 (fr) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Composés spiro utilisés en tant qu'inhibiteurs de glycosidases |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
| KR20210060513A (ko) | 2018-09-19 | 2021-05-26 | 바이오젠 엠에이 인코포레이티드 | O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제 |
| TWI716107B (zh) | 2018-09-26 | 2021-01-11 | 美商美國禮來大藥廠 | 6-氟-2-甲基苯并[d]噻唑-5-基化合物 |
| TW202039482A (zh) | 2018-12-05 | 2020-11-01 | 美商百健Ma公司 | 嗎啉基、哌嗪基、氧氮雜環庚烷基及二氮雜環庚烷基o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃醣苷酶抑制劑 |
| KR20220118483A (ko) * | 2019-12-18 | 2022-08-25 | 얀센 파마슈티카 엔.브이. | Oga 억제제 화합물 |
| BR112022011812A2 (pt) * | 2019-12-18 | 2022-08-30 | Janssen Pharmaceutica Nv | Compostos inibidores da oga |
| KR102533471B1 (ko) * | 2020-11-23 | 2023-05-19 | (주) 메디프론디비티 | O-GlcNAcase 저해 활성을 갖는 화합물 및 이의 용도 |
| WO2024081775A1 (fr) | 2022-10-14 | 2024-04-18 | Eli Lilly And Company | Synthèse de composés 6-fluoro-2-méthylbenzo[d] thiazol-5-yle |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2853891C (fr) * | 2011-12-06 | 2020-03-10 | Janssen Pharmaceutica Nv | Derives de 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine |
| SI2970272T1 (sl) * | 2013-03-14 | 2019-06-28 | Merck Patent Gmbh | Inhibitorji glikozidaze |
| HUE057317T2 (hu) * | 2014-04-23 | 2022-04-28 | Dart Neuroscience Llc | Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok |
| CN107108601B (zh) * | 2014-08-28 | 2021-08-20 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| WO2017035114A1 (fr) * | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Dérivés de benzimidazole utiles à titre d'agonistes inverses de cb-1 |
| ES2765738T3 (es) | 2015-11-02 | 2020-06-10 | Janssen Pharmaceutica Nv | Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo |
-
2017
- 2017-12-15 CA CA3044762A patent/CA3044762A1/fr not_active Abandoned
- 2017-12-15 AU AU2017378182A patent/AU2017378182A1/en not_active Abandoned
- 2017-12-15 JP JP2019532020A patent/JP2020503300A/ja active Pending
- 2017-12-15 WO PCT/EP2017/083125 patent/WO2018109198A1/fr not_active Ceased
- 2017-12-15 MA MA047576A patent/MA47576A/fr unknown
- 2017-12-15 CN CN201780086726.3A patent/CN110312716A/zh active Pending
- 2017-12-15 EP EP17825805.9A patent/EP3555094A1/fr not_active Withdrawn
- 2017-12-15 US US16/469,685 patent/US20190359609A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020503300A (ja) | 2020-01-30 |
| CN110312716A (zh) | 2019-10-08 |
| US20190359609A1 (en) | 2019-11-28 |
| AU2017378182A1 (en) | 2019-06-06 |
| CA3044762A1 (fr) | 2018-06-21 |
| WO2018109198A1 (fr) | 2018-06-21 |
| EP3555094A1 (fr) | 2019-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| EP3558322A4 (fr) | Composés benzyl-amide phosphodiamide antiviraux | |
| EP3532069A4 (fr) | Composés aryl-amide phosphodiamide antiviraux | |
| EP3720430A4 (fr) | Composés benzocarbonyle | |
| IL264458B (en) | Cannabis composition | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| MA46242A (fr) | Composés inhibiteurs de bêta-lactamase | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| EP3464275A4 (fr) | Composés inhibiteurs de l'egfr | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA42919A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| MA52939A (fr) | Composés inhibiteurs d'oga | |
| MA52942A (fr) | Composés inhibiteurs d'oga | |
| IL264461A (en) | Cannabis composition | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| MA42918A (fr) | Composés bicycliques utilisés en tant qu'inhibiteurs d'atx | |
| EP3445750A4 (fr) | Composés thérapeutiques | |
| LT4101855T (lt) | Priešnavikiniai junginiai | |
| EP3317241A4 (fr) | Composés inhibiteurs thérapeutiques | |
| EP3436003A4 (fr) | Composés bicycliques antidiabétiques | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| EP3464336A4 (fr) | Composés | |
| EP3562487A4 (fr) | Composés inhibiteurs des métalloenzymes |